Zobrazeno 1 - 10
of 143
pro vyhledávání: '"R R, Ruffolo"'
Publikováno v:
Pharmacology. 55:18-24
Molecular modeling studies have predicted that the beta-hydroxyl group of the catecholamines interacts with the beta 2-adrenoceptor at the serine residue at position 165 (Ser165) located on transmembrane helix IV; however, this has not been confirmed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97b8ae5bc68a3fd4b9f2a4f105cd74b0
https://doi.org/10.1159/000139508
https://doi.org/10.1159/000139508
Publikováno v:
Canadian Journal of Physiology and Pharmacology. 73:533-543
Adrenoceptors can be subdivided into three major types, the α1-, α2-, and β-adrenoceptors. Each of these types can be further subdivided into three subtypes, based on pharmacological characteristics. Molecular cloning techniques have supported thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84cf09c50ccce4333b3e094bac37c684
https://doi.org/10.1139/y95-068
https://doi.org/10.1139/y95-068
Autor:
Laura E. Earnest, G. Poste, T. E. Campbell, Rosemary K. Clyne, Zhongyun Dong, Christopher Seid, D. Fan, Ij Fidler, R. R. Ruffolo, Pedro J. Beltran
Publikováno v:
International journal of oncology. 4(4)
The purpose of this study was to determine whether agonists and antagonists of alpha-adrenoceptors that affect calcium fluxes and protein kinase C signal transduction alter the chemosensitivity of cancer cells that exhibit multidrug resistance (MDR).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7bcba380e1b49d797529c0380bbfaeb
https://pubmed.ncbi.nlm.nih.gov/21566983
https://pubmed.ncbi.nlm.nih.gov/21566983
Autor:
R. R. Ruffolo, J. P. Hieble
Publikováno v:
Fundamental & Clinical Pharmacology. 6:7s-13s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14c6abb6ec9862718186d6daefae6ec9
https://doi.org/10.1111/j.1472-8206.1992.tb00136.x
https://doi.org/10.1111/j.1472-8206.1992.tb00136.x
Publikováno v:
European Journal of Clinical Pharmacology. 38:S82-S88
Carvedilol is a potent antihypertensive agent with a dual mechanism of action. At relatively low concentrations it is a competitive β-adrenoceptor antagonist and a vasodilator, whereas at higher concentrations it is also a calcium channel antagonist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49e2a7469447ea5f8d84327fa6fde76a
https://doi.org/10.1007/bf01409471
https://doi.org/10.1007/bf01409471
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 298(1)
The recombinant alpha2-adrenoceptors, designated as alpha2a and alpha2d, have highly similar amino acid sequences, but distinct pharmacological properties. It has been suggested that these two receptor subtypes are species orthologs, since the alpha2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::52b3202f738934915a62e8adb54ba168
https://pubmed.ncbi.nlm.nih.gov/11408545
https://pubmed.ncbi.nlm.nih.gov/11408545
Autor:
D P, Brooks, R R, Ruffolo
Publikováno v:
Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 17(2)
Systolic hypertension is a major risk factor for cardiovascular disease. The determinants of systolic blood pressure are peripheral resistance and arterial compliance. Arterial vasoconstriction, vascular growth and fluid retention, induced by the ren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b15e0e11a408353220899a6b139e1ab
https://pubmed.ncbi.nlm.nih.gov/10465064
https://pubmed.ncbi.nlm.nih.gov/10465064
Autor:
J. P. Hieble, R. R. Ruffolo
Publikováno v:
European urology. 36
Although the selective alpha1-adrenoceptor antagonists were initially developed as antihypertensive drugs, and they are still utilized for this indication, the alpha1-adrenoceptor blockers are now used extensively for the symptomatic treatment of ben
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde53de4bdd7688a67de79e9e0b217a4
https://pubmed.ncbi.nlm.nih.gov/10393468
https://pubmed.ncbi.nlm.nih.gov/10393468
Autor:
R N, Willette, N, Aiyar, T L, Yue, M P, Mitchell, J, Disa, B L, Storer, D P, Naselsky, J M, Stadel, E H, Ohlstein, R R, Ruffolo
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 289(1)
Clinical studies conducted with carvedilol suggest that beta-adrenoceptor antagonism is an effective therapeutic approach to the treatment of heart failure. However, many beta-adrenoceptor antagonists are weak partial agonists and possess significant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::30edf1ed3b3479852cd2306c26bbe2aa
https://pubmed.ncbi.nlm.nih.gov/10086986
https://pubmed.ncbi.nlm.nih.gov/10086986